Document Type

Article

Abstract

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

Digital Object Identifier (DOI)

https://doi.org/10.1128/aac.01867-24

APA Citation

Fouad, A., Bobenchik, A. M., Chamberland, R., Clark, A. E., Huse, H. K., Martin, I. W., Mochon, A. B., Munson, E., Sfeir, M. M., Srodon, M., Taylor, K., Wang, Y., Westblade, L. F., Nicolau, D. P., & Asempa, T. E. (2025). Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024). Antimicrobial Agents and Chemotherapy, 69(5).https://doi.org/10.1128/aac.01867-24

Rights

© 2025 Fouad et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Download

Included in

Nursing Commons

Share

COinS